Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2026 Mar 9;21(3):e0344592. doi: 10.1371/journal.pone.0344592

Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins

Hanadi M Baeissa, Tahani Bakhsh, Afnan Mohammed Shakoori, Ghadir Sindi, Randa Mohammed Zaki, Mohammad Azhar Kamal, Hadeel A Alsufyani, Alaa Hamed Habib, Arwa Ishaq A Khayyat, Misbahuddin Rafeeq, Deeba Shamim Jairajpuri
PMCID: PMC12970878  PMID: 41801824

The Funding statement for this article is incorrect. The correct Funding statement is as follows: This study is supported by Prince Sattam bin Abdulaziz University, project number PSAU/2024/R/1445

Reference

  • 1.Baeissa HM, Bakhsh T, Shakoori AM, Sindi G, Zaki RM, Kamal MA, et al. Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins. PLoS One. 2025;20(10):e0334013. doi: 10.1371/journal.pone.0334013 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLOS One are provided here courtesy of PLOS

RESOURCES